title: Insulin-induced electrophysiology changes in human pleura are mediated via its receptor.
abstract: BACKGROUND
  Insulin directly changes the sheep pleural electrophysiology. The aim of this study was to investigate whether insulin induces similar effects in human pleura, to clarify insulin receptor's involvement, and to demonstrate if glibenclamide (hypoglycemic agent) reverses this effect.
  
  
  METHODS
  Human parietal pleural specimens were mounted in Ussing chambers. Solutions containing insulin or glibenclamide and insulin with anti-insulin antibody, anti-insulin receptor antibody, and glibenclamide were used. The transmesothelial resistance (R(TM)) was determined. Immunohistochemistry for the presence of Insulin Receptors (IRa, IRb) was also performed.
  
  
  RESULTS
  Insulin increased R(TM) within 1st min (P = .016), when added mesothelially which was inhibited by the anti-insulin and anti-insulin receptor antibodies. Glibenclamide also eliminated the insulin-induced changes. Immunohistochemistry verified the presence of IRa and IRb.
  
  
  CONCLUSIONS
  Insulin induces electrochemical changes in humans as in sheep via interaction with its receptor. This effect is abolished by glibenclamide.
authors.affiliation: Department of Physiology, Medical School, University of Thessaly, Mezourlo, New Buildings, Larissa, Greece. kouritas@otenet.gr
authors.forename: V K
authors.initials: VK
authors.lastname: Kouritas
authors.forename: M
authors.initials: M
authors.lastname: Ioannou
authors.forename: C N
authors.initials: CN
authors.lastname: Foroulis
authors.forename: N
authors.initials: N
authors.lastname: Desimonas
authors.forename: K
authors.initials: K
authors.lastname: Evaggelopoulos
authors.forename: K I
authors.initials: KI
authors.lastname: Gourgoulianis
authors.forename: P A
authors.initials: PA
authors.lastname: Molyvdas
authors.forename: C
authors.initials: C
authors.lastname: Hatzoglou
mesh_terms: D005905:Glyburide / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D010994:Pleura / Q000187:drug effects* / Q000502:physiology; D017526:Receptor, IGF Type 1 / Q000502:physiology; D011972:Receptor, Insulin / Q000032:analysis / Q000502:physiology*
chemical_list: D007328:Insulin; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin; D005905:Glyburide
references.citation: Br J Pharmacol. 2000 Jul;130(6):1255-62
references.pmid: 10903963
references.citation: J Pharmacol Exp Ther. 1993 May;265(2):933-7
references.pmid: 8496833
references.citation: J Gen Physiol. 1999 Oct;114(4):561-74
references.pmid: 10498674
references.citation: J Am Soc Nephrol. 2007 Jun;18(6):1652-61
references.pmid: 17442787
references.citation: Eur J Gastroenterol Hepatol. 2003 May;15(5):545-9
references.pmid: 12702914
references.citation: Exp Clin Endocrinol Diabetes. 1996;104(1):1-9
references.pmid: 8750563
references.citation: Eur Respir J. 2007 Aug;30(2):354-7
references.pmid: 17666558
references.citation: Am J Physiol. 1977 Mar;232(3):F270-7
references.pmid: 402826
references.citation: Am J Physiol. 1998 May;274(5):C1373-9
references.pmid: 9612225
references.citation: J Pharmacol Exp Ther. 2003 Feb;304(2):833-40
references.pmid: 12538840
references.citation: J Membr Biol. 1999 Mar 1;168(1):91-101
references.pmid: 10051692
references.citation: Am J Physiol. 1985 Jul;249(1 Pt 2):F1-11
references.pmid: 3893158
references.citation: Br J Pharmacol. 2005 Aug;145(8):1069-75
references.pmid: 15912128
references.citation: Br J Pharmacol. 2000 Aug;130(7):1678-84
references.pmid: 10928974
references.citation: Am J Physiol. 1984 Nov;247(5 Pt 1):C472-7
references.pmid: 6093574
references.citation: Am J Physiol. 1992 Jan;262(1 Pt 1):C207-13
references.pmid: 1310212
references.citation: Diabetes. 1993 Jul;42(7):1032-40
references.pmid: 8513970
references.citation: Biochem Biophys Res Commun. 2002 Feb 22;291(2):394-9
references.pmid: 11846418
references.citation: Biol Pharm Bull. 2001 Apr;24(4):385-9
references.pmid: 11305600
references.citation: J Appl Physiol (1985). 2001 Apr;90(4):1565-9
references.pmid: 11247961
references.citation: J Pharm Sci. 2002 Apr;91(4):1135-46
references.pmid: 11948552
references.citation: Diabet Med. 2007 Nov;24(11):1282-5
references.pmid: 17956453
references.citation: Am J Physiol. 1989 Oct;257(4 Pt 1):C612-20
references.pmid: 2552816
references.citation: Am J Physiol. 1965 Oct;209(4):819-24
references.pmid: 5843433
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):213-25
references.pmid: 8878050
references.citation: Am J Kidney Dis. 2004 Oct;44(4):575-90
references.pmid: 15384008
references.citation: Physiol Rev. 2004 Apr;84(2):385-410
references.pmid: 15044678
references.citation: Endocr Rev. 1999 Apr;20(2):101-35
references.pmid: 10204114
references.citation: Exp Clin Endocrinol Diabetes. 2010 May;118(5):304-9
references.pmid: 19856254
references.citation: J Vet Med A Physiol Pathol Clin Med. 2006 Feb;53(1):5-11
references.pmid: 16411900
references.citation: Am J Physiol Cell Physiol. 2004 Mar;286(3):C586-95
references.pmid: 14592811
references.citation: Pflugers Arch. 1996 Aug;432(4):685-91
references.pmid: 8764970
references.citation: Pflugers Arch. 2005 Dec;451(3):445-53
references.pmid: 16170524
references.citation: J Investig Med. 2004 Mar;52(2):104-8
references.pmid: 15068225
references.citation: Physiol Rev. 2003 Oct;83(4):1113-51
references.pmid: 14506302